Vous avez cherché: pain (Italien - Danois)

dogs treatment of pain & inflammation
dogs treatment of pain & inflammation

cats alleviation of pain and inflammation
cats alleviation of pain and inflammation

dogs post-operative pain (qm01ac06)
dogs post- operative pain (qm01ac06)

v10bx02 therapeutic radiopharmaceutical for pain palliation
v10bx02 therapeutic radiopharmaceutical for pain palliation

dogs control of inflammation and relief of pain
dogs control of inflammation and relief of pain

che cos’ è lacosamide pain ucb pharma?
hvad er lacosamid pain ucb pharma?

treatment of chronic pain requiring intraspinal analgesia
treatment of chronic pain requiring intraspinal analgesia

- horses - relief of pain associated with colic
- horses - relief of pain associated with colic

m01ah for the short-term treatment of postoperative pain
m01ah for the short- term treatment of postoperative pain

note for guidance on clinical investigation of medicinal products for treatment of pain
note for guidance on clinical investigation of medicinal products in the treatment of epileptic disorders

dogs initiation therapy for alleviation of pain and inflammation (qm01ac06)
dogs initiation therapy for alleviation of pain and inflammation (qm01ac06)

investigation of medicinal products in pain management points to consider on pharmaco-kinetics
concept paper on the development of a cpmp note for guidance on the clinical investigation of medicinal products in pain management

ma c' è- come dicono i francesi- du pain sur la planche.
men der er- som franskmændene siger- du pain sur la planche.

domande e risposte sul ritiro della domanda di autorizzazione all’ immissione in commercio per lacosamide pain ucb pharma
spørgsmål og svar vedrørende tilbagetrækningen af ansøgningen om markedsføringstilladelse for lacosamid pain ucb pharma

quali sono le conseguenze del ritiro per i pazienti inseriti in studi clinici o in programmi di uso compassionevole con lacosamide pain ucb pharma?
hvilke konsekvenser har tilbagetrækningen for patienter, der deltager i kliniske undersøgelser med lacosamid pain ucb pharma eller i programmer for anvendelse med særlig udleveringstilladelse?

note for guidance on clinical investigation of medicinal products for treatment of nociceptive pain concept paper on the development of a cpmp note for guidance on clinical investigation of medicinal products for the treatment of generalised anxiety disorder
concept paper on the development of a cpmp note for guidance on clinical investigation of medicinal products for the treatment of generalised anxiety disorder

in tutti e quattro gli studi, la dose di lacosamide pain ucb pharma è stata gradualmente aumentata nel corso di poche settimane prima di essere mantenuta ad un dosaggio stabile per 12 settimane.
i alle fire undersøgelser blev dosen af lacosamid pain ucb pharma gradvist forøget over nogle få uger og var herefter fast i 12 uger.

pertanto, al momento del ritiro della domanda, era opinione del chmp che i benefici di lacosamide pain ucb pharma non fossero stati sufficientemente dimostrati e che comunque non fossero superiori ai rischi identificati.
på tilbagetrækningstidspunktet var det derfor chmp' s opfattelse, at fordelene ved lacosamid pain ucb pharma ikke var blevet tilstrækkeligt påvist, og at de eventuelle fordele ikke opvejede de påviste risici.

8 due studi di breve durata, 95-001 (dolore maligno) e 96-002 (dolore non maligno), condotti su 366 pazienti, dimostrano l’ efficacia di ziconotide somministrato per via intratecale per il trattamento del dolore cronico di grado severo usando la variazione delle percentuali nella visual analog scale of pain intensità (vaspi) come principale misura dell’ efficacia.
til måling af primær effekt blev der anvendt en visuel analog skala (vas- skala) til måling af smerteintensitet.